Publication | Closed Access

GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response

Cancer ImmunosurveillanceGanoderma LucidumMalignant DiseaseMedicineBioactive Proteoglycan FractionGlycobiologyImmunologyPathologyAnti-tumour ActivityImmunoeditingImmunotherapyCancer BiologyCell BiologyTumor MicroenvironmentTumor Biology